# Siva Samy

> Dr. Siva Samy is the founder, CEO, and Chief Product Strategist of ValGenesis, the global leader in digital validation lifecycle management for the life sciences industry. He built the first platform to fully digitize and automate the pharmaceutical validation process - the compliance-critical system that ensures every drug, device, and biotech product is manufactured correctly. Under his leadership, ValGenesis has become trusted by 30 of the top 50 global life sciences companies and has raised over $40 million in funding, including a $24M investment from Morgan Stanley Expansion Capital and a $16M debt financing in 2025.

- **Role:** CEO & Chief Product Strategist at ValGenesis
- **Organizations:** ValGenesis
- **Nationality:** Indian-American
- **Education:** Master's degree in Analytical Chemistry, University of Madras, Ph.D. in Medical Devices, University of Toronto, Post-doctoral fellowship, University of Toronto / University of Madras
- **Known for:** Founded ValGenesis, the global leader in digital validation lifecycle management, Built the first 100% end-to-end paperless validation solution in life sciences, Trusted by 30 of the top 50 global life sciences companies

## Career timeline

- **Pre-2003** — Held technical and management roles at biotech, pharma, and medical device companies including Xoma, 3M, and Guidant
- **2003** — Founded ValGenesis to digitize the pharmaceutical validation lifecycle
- **2005** — ValGenesis received the Parenteral Drug Association (PDA) New Innovative Technology Award
- **2021** — Secured $24 million investment from Morgan Stanley Expansion Capital
- **2024** — Launched VLMS 5.0 with industry-first AI capabilities at ValConnect 2024 in Lisbon, Portugal
- **2025-06** — Launched ValGenesis Smart GxP - the first AI-enabled platform to unify validation and process lifecycle management
- **2025-07** — Secured $16 million strategic financing from Bridge Bank / Innovation Banking Group to accelerate global expansion and AI innovation
- **2026** — Launched next generation of VAL (ValGenesis AI), enabling up to 80% reduction in validation time and cost; scheduled to speak at Interphex Week Tokyo (May 2026) and ISPE Annual Meeting & Expo (October 2026)

## Achievements

- Founded ValGenesis, the global leader in digital validation lifecycle management
- Built the first 100% end-to-end paperless validation solution in life sciences
- Trusted by 30 of the top 50 global life sciences companies
- Authored 15+ peer-reviewed research articles
- Holds a USPTO patent: 'Validating and Maintaining Respective Validation Status of Software Applications, Manufacturing Systems and Business Processes'
- Raised $40+ million in total funding for ValGenesis including $24M from Morgan Stanley Expansion Capital
- ValGenesis received the PDA New Innovative Technology Award (2005)
- Launched industry-first AI-enabled validation platform (Smart GxP, 2025)
- Expanded ValGenesis globally with offices/subsidiaries in North America, Europe, and Asia-Pacific

## Latest updates

- **2026-04** — ValGenesis launched the next generation of VAL (ValGenesis AI), bringing governed AI to the full validation lifecycle with up to 80% time and cost savings
- **2025-07** — ValGenesis raised $16M in strategic debt financing from Bridge Bank to accelerate global expansion and AI-driven innovation
- **2025-06** — ValGenesis launched Smart GxP, the first AI-enabled platform to unify validation and process lifecycle management in life sciences
- **2025-07** — ValGenesis partnered with CAI to advance AI-enabled digital validation in life sciences
- **2024-06** — ValGenesis unveiled VLMS 5.0 with AI capabilities at ValConnect 2024 in Lisbon, Portugal

## Links

- Website: https://valgenesis.com
- LinkedIn: http://www.linkedin.com/in/sisamy
- Twitter/X: https://twitter.com/ValgenesisInc
- Facebook: https://facebook.com/ValGenesis.Inc/

---

Profile page: https://yespress.io/siva-samy
Published by YesPress — https://yespress.io
Last updated: 2026-05-15